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In vitro selections of mammaglobin 
A and mammaglobin B aptamers 
for the recognition of circulating 
breast tumor cells
Eman M. Hassan1,4, William G. Willmore2,3, Bruce C. McKay2,3 & Maria C. DeRosa2,4
Mammaglobin B (MGB2) and mammaglobin A (MGB1) are proteins expressed in metastatic breast 
cancers. The early detection of circulating tumor cells (CTCs) in breast cancer patients is crucial to 
decrease mortality rate. Herein, novel aptamers were successfully selected and characterized against 
MGB2 and MGB1 proteins using a hybrid SELEX approach. The potential use of the selected aptamers 
in breast CTC detection was studied using spiked breast cancer cells in whole blood lysate. The results 
obtained from this study showed that the selected aptamers (MAMB1 and MAMA2) bind to their target 
breast cancer cell lines with high affinity (low nanomolar Kd values) and specificity. They also bind to 
their free recombinant target proteins and show minimal non-specific binding to normal and other 
cancer cell lines. Additionally, they were able to distinguish a low number of breast cancer cells spiked in 
whole blood lysate containing normal blood cells. The results obtained in this study indicate the great 
potential for the use of aptamers to detect MGB1 and MGB2 protein biomarkers, expressed on the 
surface of breast CTCs.
Cancer is a complex disease that originates as a result of multiple genomic mutations leading to a disruption of 
normal cellular homeostasis1. Breast cancer is the most common cancer diagnosed in women, with an estimated 
1.67 million new cases diagnosed worldwide in 20122. One in eight U.S. women (about 12%) will develop invasive 
breast cancer over the course of their lifetime3. In 2016, an estimated 246,660 new cases of invasive breast cancer 
are expected to be diagnosed in women in the U.S3. Metastasis is the main cause of death for the majority of breast 
cancer patients4. To date, few biomarkers are used to detect metastatic breast cancer5–7. Further identification of 
promising biomarkers would be of great benefit in the field of breast cancer diagnosis and therapy.
Circulating tumor cells (CTCs) are cells that are shed from the primary tumor and start to invade surround-
ing tissues, intravasate into the blood stream to circulate with its components, extravasate to distant tissues in 
different organs, start to adapt to the new microenvironment, and proliferate starting a secondary tumor8. To 
initiate metastasis, cancer cells transform from an epithelial form to a mesenchymal form in a process known 
as epithelial-to-mesenchymal transition (EMT)9. In EMT, cancer cells gain new properties including increased 
invasive capacity, higher resistance to apoptosis, and a noticeable increase in the extracellular matrix (ECM) 
components10,11. The changes are reversible and, once the cancer cells reach their destination, they regain their 
epithelial properties in a process called mesenchymal-to-epithelial transition (MET)12.
Mammaglobin B (MGB2) and Mammaglobin A (MGB1) are secretory proteins and members of the uteroglo-
bin gene family13,14. Both are small proteins (approximately 10 kDa) that contain an alpha-helix in their structure 
and are often found as dimers15,16. Little is known about their function, but it is believed that they have a role in 
cancer development, immune system regulation, and the transport of aromatic molecules, such as steroid hor-
mones17. MGB2 and MGB1 have been reported to be highly homologous (58% homology) and are thought to 
perform the same biological functions13. MGB2 is mostly expressed in mucosal tissues and is found at high levels 
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in many secretions including those from uterine, prostatic, pulmonary, and lacrimal and salivary glands13,14,18,19. 
MGB2 is overexpressed in ovarian and endometrium cancers, as well as all primary and metastatic breast can-
cers20–22. In contrast, MGB1 overexpression is only limited to breast cancer22,23. Both of the proteins have been 
reported as markers of breast cancer micro-metastases to lymph nodes and markers of CTCs found in the blood 
of breast cancer patients24–29.
The development of highly specific recognition probes against MGB2 and MGB1 will aid in the diagnosis of 
breast cancer and CTCs from breast cancer tumors. Aptamers are powerful molecular recognition probes30. They 
are synthetic, short (∼15–100 nucleotides in length) single stranded DNA or RNA oligonucleotides that recog-
nize molecular targets, such as biomarkers, through a unique three-dimensional interaction with the target with 
high affinity and specificity30. Aptamers are produced via an in vitro selection method called Systematic Evolution 
of Ligands by EXponential enrichment (SELEX) by the repetitive partitioning of binders from a large library of 
oligonucleotides having an initial diversity of 1013–1015 random sequences30,31. Each round of aptamer selection 
in SELEX is performed by binding and eluting aptamers from target molecules or cells, leading to the selection of 
aptamers from the library with high affinity and specificity for their targets32,33. Compared to their broadly-used 
antibody counterparts, aptamers possess unique properties in that they can be easily synthesized and have the 
ability to be chemically modified, which makes aptamers more convenient to use as molecular probes for various 
applications34–36.
Cell-SELEX is a powerful tool for the identification of new biomarkers33. However, the cell has a large number 
of surface molecules and potential target biomarkers, making potential nonspecific interactions of great con-
cern37,38. Many additional steps have been introduced to cell-SELEX to overcome this obstacle, including counter 
selection steps39. Hybrid, or cross-over cell-SELEX, allows for the selection of specific biomarkers on the surface 
of the cell by alternating the SELEX process between a purified recombinant protein of interest, and the cells that 
express this protein, as targets40,41. Unlike whole cell-SELEX, where the knowledge of the biomarker is not neces-
sary to develop aptamers specific for a certain cell line, hybrid SELEX determines the biomarker of interest before 
the SELEX process takes place42. Hybrid SELEX produces highly enriched aptamers against the target of interest 
(biomarker) on the surface of the cell. Moreover, aptamers selected by hybrid SELEX are potentially more specific 
to the tumor cell line, versus the control, than aptamers developed utilizing whole cells as targets42.
In this study, a series of aptamers against MGB2 and MGB1 was developed, for the first time, using the hybrid 
cell-SELEX approach (Fig. 1). Characterization of the selected aptamers, against relevant cell targets and the free 
recombinant protein, were evaluated using flow cytometry, fluorescence microscopy, and electrophoretic mobility 
shift assay. Selected aptamers were used to test their ability to detect breast cancer cells in plasma and whole blood 
lysate-like environments. The ability of the aptamers to detect spiked breast cancer cells in a mixture of whole 
blood lysate containing normal blood cells was investigated. Additionally, cell-aptamer binding studies were per-
formed to verify the protein target of the aptamers selected.
Figure 1. Schematic diagram of hybrid SELEX method for selection of MGB2 and MGB1-specific DNA 
aptamers. Hybrid SELEX is divided into (A) a protein-based SELEX in which GST-MGB2 conjugated beads 
(brown) and GST-MGB1 proteins conjugated beads (purple) were used. The protein SELEX was done for 21 
rounds for MGB2 and 4 round for MGB1. Subsequently, the enriched pools of both proteins were transferred 
to cells (B) to start cell-based SELEX in which HCAEC and MCF10A were used as counter selection cell lines. 
MCF7 was used as the target selection cell line for MGB2 and MDA-MB-415 was used as the target selection 
cell line for MGB1. After 7 rounds of cell-SELEX to each target cell line, the final pools for both targets were 
transferred back to the proteins for another 2 additional rounds for each MGB2 and MGB1 to make the library 
more specific to MGB2 and MGB1.
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Results and Discussion
Hybrid SELEX analysis: Development of aptamers that bind specifically to MGB2 and MGB1 
proteins. Monitoring the enrichment of the ssDNA library during protein- and cell-SELEX. In this study, we 
modified the cell-SELEX protocol37 by introducing a purified protein SELEX before initiating cell-SELEX (hybrid 
SELEX) to enrich the ssDNA library for aptamers with specificity towards MGB2 and MGB1. The percentage 
recovery of the ssDNA libraries (during protein SELEX) for both recombinant glutathione S-transferase (GST)-
tagged MGB2 and MGB1 was monitored by measuring fluorescein emission (520 nm) from aptamer fractions 
eluted from glutathione modified beads (Fig. 2A and B). Figure 2A shows an increase in the percentage recov-
ery of DNA with increasing numbers of selection rounds of MGB2, while recovery of DNA from GST-protein 
decreased from an initial high amount to remain consistently lower than the positive elutions. No increase in 
recovery from positive elutions was seen after rounds 13 to 15, suggesting that enrichment reached a maximum 
at round 13. Due to the fact that MGB2 and MGB1 are similar, MGB1 was used as a counter selection to eliminate 
cross-reacting sequences (rounds 16, 17 and 18) resulting in the division of the ssDNA library in almost two equal 
parts (splitting the main ssDNA library), as indicated by the percentage recovery for MGB2 (Round 16) shown 
Figure 2. Monitoring the enrichment of ssDNA library of MGB2 and MGB1 during hybrid SELEX. (A) 
Percentage recovery of MGB2 library during protein SELEX. GST-protein (blue) was used for counter selection 
throughout the selection. MGB1 protein (green) was used as the counter selection target in R16 to R18 to 
split the main library into two parts to eliminate the sequences that could bind to MGB1 and MGB2 targets 
together. (B) Percentage recovery of MGB1 protein library during protein SELEX. R17 counter selection (green) 
from MGB2 SELEX was used as the initial ssDNA library of MGB1 SELEX. The percentage recovery for both 
proteins SELEX was measured as the emission of FAM labelled ssDNA libraries at 520 nm. (C) The fluorescence 
intensity (FL1-A) of MCF7 (MGB2 positive cell line) when binding to R0, R21, and R30 of MGB2. (D) The 
fluorescence intensity (FL1-A) of MDA-MB-415 (MGB1 positive cell line) when binding to R0, R4, and R13 of 
MGB1. (E,F) The fluorescence intensity (FL1-A) of HCAEC cells and MCF10A (counter cell lines) respectively 
when binding to R0, R21 MGB2, R4 MGB1, R30 MCF7 and R13 MDA-MB-415. The fluorescence intensity 
was measured using flow cytometry by incubating the 6-FAM tagged ssDNA with the cells for 30 min at 4 °C in 
PBS. The fluorescence intensity of cells from all cell lines (control/background signal) was subtracted from the 
fluorescence intensity of the positive and counter cell lines and included in the graph.
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in Fig. 2A. This is matched our expectations, since MGB2 and MGB1 are 58% alike13. The Round 17 counter 
selection pool was used as the initial ssDNA library for MGB1 SELEX due to its higher enrichment with MGB1-
binding sequences (Fig. 2A and B). The final DNA percentage recovery eluted from both proteins was similar, 
indicating high enrichment (around 4.8%).
To develop aptamers against metastatic breast cancer, MCF7 and MDA-MB-415 breast cancer cell lines 
derived from metastatic sites were used in the cell-SELEX and the expression of MGB2 and MGB1 in both 
cell lines, as well as the counter selection cell lines (MCF10A and HCAEC), was evaluated using ELISA. Our 
results confirmed that the MGB2 and MGB1 proteins are exclusively expressed on the surface of MCF7 and 
MDA-MB-415 cells respectively, compared to other cell lines used in the SELEX (Supplementary Fig. S1) which 
confirms the results found in previous studies13,14.
Flow cytometry was used to monitor the enrichment of ssDNA libraries during cell-SELEX. A clear shift in fluo-
rescence intensity was observed in Round 30 of MCF7 (MGB2) compared to Round 21 (end of protein-SELEX) and 
Round 0 (Fig. 2C). Higher fluorescence intensity shift was observed in R13 of MDA-MB-415 (MGB1) compared to 
R4 (end of protein-SELEX) and R0 (Fig. 2D). The counter selection cell lines did not show a change in the fluorescence 
intensity, indicating the specificity of the aptamers selected for the MCF7 and MDA-MB-415 cell lines (Fig. 2E and F).
High throughput sequencing (HTS) and bioinformatics analysis. Our SELEX method included a 
number of targets (proteins and cell lines) and therefore HTS was preferable due to its many advantages over tra-
ditional cloning and sequencing43. Specifically, the ability to efficiently compare sequences from multiple rounds 
with varying conditions in a statistically robust fashion. The high throughput datasets for both targets were 
grouped into clusters using AptaCluster software, according to their similarity. Each cluster contained sequences 
that were arranged according to their enrichment and count. The overall analysis of MGB2 and MGB1 sequences 
showed that MBG2 aptamers seemed to be more C-rich, while MGB1 aptamers were more T-rich, compared to 
aptamers in Round 0 (according to bioinformatics analysis using AptaCluster as a software). The analysis of the 
random region (N) of both MGB2 and MGB1 sequences showed that the dominant length of N was 25 bases 
(one more than what was present in the original synthesized pool) and 24 bases for MGB2 and MGB1 sequences 
respectively, indicating that mutations took place during the selection process, for example during PCR amplifi-
cation (Supplementary Fig. S2). Comparing enrichment of a sequence (rather than just the copy number) from 
early to later selection rounds should minimize artifacts from PCR bias and allow for the choice of sequences with 
improved aptamer-target binding. Twelve MGB2 and eight MGB1 aptamers were chosen from the final pools 
for further study, based on their enrichment in the last round of selection, compared to Round 0. The secondary 
structure of all candidate aptamers was predicted using RNA structure software (Supplementary Fig. S3).
Screening for the binding affinity of the selected aptamers and Kd determination. Applying the 
hybrid SELEX methodology allowed us to obtain aptamers that were expected to be specific both to the target pro-
tein and to tumor cells expressing the same target biomarker (in this case, MGB2 or MGB1). To evaluate the binding 
affinity, all selected aptamers were labelled with 6-FAM on the 5′ end and were subjected to flow cytometry analysis 
against the target and counter selection cell lines. As Fig. 3 shows, six out of twelve aptamers of MGB2 and four out 
of eight of MGB1 aptamers showed higher binding affinity to MCF7, compared to MCF10A and HCAEC cell lines 
(Fig. 3A and B). These aptamers were selected for further characterization to determine their Kd values (against their 
target cell lines) (Table 1 and Supplementary Table 1). All Kd values obtained here were in the nanomolar range, 
which is typical for aptamers developed against cancer cells using cell-SELEX44. MGB2 selected aptamers showed Kd 
values in the low nanomolar range (from 13 to 105 nM; Table 1). MAMB1 and MAMB12 showed the highest affinity 
(lowest Kd values) (Table 1) of 14 ± 3 nM and 20 ± 6 nM respectively (Fig. 4A). However, all MGB1 selected aptamers 
showed nanomolar affinity for the MDA-MB-415 cell line, with Kd values from 3 to 54 nM (Table 1). MAMA12 and 
MAMA2 aptamers showed the lowest Kd values, with values of 8 ± 3 nM and 3 ± 1 nM for MAMA12 and MAMA2, 
respectively. This indicated that both aptamers have a high affinity for the MDA-MB-415 cell line (Fig. 4C). Notably, 
their predicted secondary structures were very simple (Fig. 4B and D), however, the structure of these aptamers may 
become more complex when interacting with their targets.
Binding selectivity of MAMB1, MAMB12 and MAMA2, MAMA12 aptamers to cancer and nor-
mal cell lines. The binding selectivity was further tested for MAMB1, MAMB12, and MAMA2, MAMA12 
aptamers for normal and cancer cell lines. As expected, MAMB1 and MAMB12 bound with highest affinity to 
their target cell line MCF7, but no binding was observed to the other breast cancer cell lines MDA-MB-415 and 
the triple negative MDA-MB-213, which are known to not express MGB2 protein13,14. MGB2 is expressed in 
different tissues13,17,18 and therefore MGB2 selected aptamers (MAMAB1 and MAMB12) showed low level of 
binding to cell lines other than breast cancer cell lines, such as HeLa and HepG2 cells (Table 2). MGB1 aptamers 
(MAMA2 and MAMA12) were found to only recognize breast cancer cells due to the fact that the MGB1 protein 
is only expressed in breast tissue; making it a potentially specific biomarker.
Binding of MAMB1 and MAMA2 to their target breast cancer cells by fluorescence microscopy. 
MAMB1 and MAMA2 aptamers showed high specific binding to their target breast cancer cells lines MCF7 and 
MDA-MB-415 respectively (Fig. 5A and D). MAMB1 did not show any binding to MDA-MB-415 (Fig. 5F), and same 
was observed with MAMA2 against MCF7 (Fig. 5C), which matches our expectations since the pool was divided into 
two parts when MGB1 was used as a counter selection target in the protein-SELEX. No binding was observed when 
both aptamers were incubated with a random sequence (dopamine aptamer) (Fig. 5B and E). No affinity of both aptam-
ers was observed when they were incubated with counter cell lines (HCAEC and MCF10A) or other cancer and normal 
cell lines (Supplementary Fig. S4A–R). The fluorescence microscopy results matched the selectivity results obtained by 
flow cytometry, indicating that both aptamers are selective to their breast cancer cells using these two methods.
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MAMB1 and MAMA2 bind to their target proteins using Electrophoretic Mobility Shift Assay 
(EMSA). Due to their high affinity and specificity (low Kd values) to their target cell lines, MAMB1 and 
MAMA2 aptamers were chosen to test their ability to interact with the target recombinant proteins that were used 
in the protein portion (MGB2 and MGB1) of the SELEX process. Utilizing EMSA with different concentrations 
of the recombinant proteins (0 to 220 nM) and a fixed concentration of the aptamer (600 nM), the results revealed 
that the aptamer-protein complex bands shifted upwards with increasing concentrations of the MGB2 and MGB1 
proteins with their respective aptamers (Supplementary Fig. S5A and S5E).
MGB1-MAMA2 complex bands showed a higher mobility shift (Supplementary Fig.  S5E) than 
MGB2-MAMB1 complex bands (60–220 nM). (Supplementary Fig. S5A). To confirm that the mobility shift was 
due to true binding of the aptamers to their target proteins, a dopamine DNA aptamer45 was incubated with 
Figure 3. Screening results of the aptamer candidates against cell-SELEX cell lines using flow cytometry. (A) 
Screening results of MGB2 aptamers show six aptamers out of twelve (MAMB0, MAMB1, MAMB4, MAMB8, 
MAMB12, MAMB57) with higher fluorescence intensity in the target selection cell line than counter selection 
ones. (B) Screening results of MGB1 aptamers show four aptamers out of eight (MAMA2, MAMA5, MAMA6, 
and MAMA12) with higher fluorescence intensity in the target selection cell line than counter selection ones. 
Promising aptamers were chosen for further studies. The experiments were repeated twice. Values are shown as 
means ± S.E.M.
Aptamer Aptamer sequence (5′-3′)a Kd (nM)
MAMB0 CATGCTTACCTATAGTGAACCCCAACACACGTGTAGATCCTGCGGCTTTGAGAACTGACTCATAC 80 ± 14
MAMB1 CATGCTTACCTATAGTGAACCCAACGTCGAACTGAATCCCGTGTCCTTTGAGAACTGACTCATAC 13 ± 3
MAMB4 CATGCTTACCTATAGTGAACGCGGCATGTTGGCATCTTGGTCCTGCTTTGAGAACTGACTCATAC 105 ± 20
MAMB8 CATGCTTACCTATAGTGAACCACGACACGCGCGATCGTCTCACTGCTTTGAGAACTGACTCATAC 78 ± 15
MAMB12 CATGCTTACCTATAGTGAACCCACCACACAGCGGATACACCATGGCTTTGAGAACTGACTCATAC 19 ± 5
MAMB57 CATGCTTACCTATAGTGAACCCGAAGAGGATGTGCGGTCCCATTGCTTTGAGAACTGACTCATAC 72 ± 9
MAMA2 CATGCTTACCTATAGTGAACCCGGGACAGAACGTGCGCTTTGAGCTTTGAGAACTGACTCATAC 3 ± 1
MAMA5 CATGCTTACCTATAGTGAACGGTTGGCATCTTGGTCCTGCTTTGCTTTGAGAACTGACTCATAC 54 ± 13
MAMA6 CATGCTTACCTATAGTGAACTGTTGGCATCTTGGTCCTGCTTTGCTTTGAGAACTGACTCATAC 49 ± 20
MAMA12 CATGCTTACCTATAGTGAACGTTGGCATCTTGGTCCTGCTTTGACTTTGAGAACTGACTCATAC 8 ± 3
Table 1. Aptamer sequences of MGB2 and MGB1 targets and their corresponding Kd values.
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the same concentrations of both proteins and used as a control. The control experiment results showed no sig-
nificant shift of both aptamers when incubated with the control aptamer compared to the shifting of MAMB1 
and MAMA2 aptamers with their target proteins (Supplementary Fig. S5B and S5F). Bovine Serum Albumin 
(BSA) protein was used as a second control, and EMSA results showed no significant shifting when MAMB1 and 
MAMA2 aptamers were incubated with BSA (Supplementary Fig. S5C and S5F). Both aptamer showed affinities 
in the nanomolar range, as indicated by plotting the different concentrations of aptamers (on the x-axis) against 
the shifting distance (cm) (Supplementary Fig. S5D and S5H).
Figure 4. Binding curves of 6-FAM-labeled aptamers to MCF7 and MDA-MB-415 target cell lines. (A) 
MAMB1 Kd curve: MCF7 cells were incubated with increasing concentrations (nM) of MAMB1 then was 
evaluated by flow cytometry. (B) The predicted secondary structure of MAMB1 aptamer using RNAstructure 
software. (C) MAMA2 Kd curve: MDA-MB-415 cells were incubated with increasing concentrations (nM) of 
MAMA2 then was evaluated by flow cytometry. (D) The predicted secondary structure of MAMA2 aptamer 
using RNAstructure software. To calculate the apparent Kd of the interaction of MAMB1 and MAMA2 to their 
corresponding cell lines, the mean fluorescence intensity of the aptamer-cell dissociation vs. concentration was 
fit to the equation Y=Bmax X/(Kd+X). R0 ssDNA library was used as control. The Kd graphs are the average of 
three trials. Values are shown as means ± S.E.M.
Cell line MAMB1 MAMB12 MAMA2 MAMA12
MCF7 ++++ ++++ + +
WI38 + + − −
HEK-293 + + − −
MDA-MB-415 − − +++ +++
HeLa + − − −
HepG2 + + − −
MDA-MB-231 − − − −
Table 2. Selectivity of MAMB1, MAMB12, MAMA2, MAMA12 aptamer to other normal and cancer cell lines. 
The selectivity of the chosen aptamers to the different cell lines were calculated based on the relative binding 
capacity of the target cell line. A cut off 15% was determined according to the binding capacity. −<15, + 
>15–30%, ++ >30–45%, +++>45–60%, ++++>60–75%.
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MAMB1 and MAMA2 targets on the surface of target breast cancer cells. In order to confirm that 
the selected aptamers are in fact binding to their anticipated biomarkers, a transfection approach was used that 
has been previously employed to identify aptamer target on the surface of cells after cell-SELEX46,47.
HEK293 cells were chosen to investigate the targets of MAMB1 and MAMA2. HEK293 are derived from 
human embryonic kidney cells and are widely used as a host for gene expression48. Therefore, they were used as 
a host for MGB2 and MGB1 plasmids. HEK293 was proven not to express MGB2 and MGB1 proteins compared 
to target breast cancer cells (MCF7 and MDA-MB-415) using ELISA kits (Supplementary Fig. S6). Moreover, 
transfected HEK293 cells were used in the competition studies using monoclonal anti-MGB2 and anti-MGB1, 
MAMB1 and MAMA2. The results showed that both aptamers and antibodies did not bind to non-transfected 
HEK293 cells, but showed binding to MCF7 and MDA-MB-415 cells (Fig. 6). This binding was 20-fold more to 
transfected HEK293 when incubated with MAMB1 and MAMA2 aptamers, and 10-fold more when incubated 
with MGB2 and MGB1 antibodies (Fig. 7A).
It was also observed that both aptamers and antibodies compete on the same binding sites of MGB2 and 
MGB1 overexpressed proteins on the surface of transfected HEK293 cells (Fig. 7B). When transfected HEK293 
cells (with either MGB2- or MGB1-expressing plasmids) were blocked with unlabeled MAMB1 and MAMA2 
Figure 5. Fluorescence microscopy images of aptamers MAMB1 and MAMA2 binding to target breast cancer 
cell lines. (A) MAMB1 binding to MCF7 cells, (B) random sequence binding to MCF7, (C) MAMA2 binding 
to MCF7. (D) MAMA2 binding to MDA-MB-415 cells, (E) random sequence binding to MDA-MB-415, (F) 
MAMB1 binding to MDA-MB-415. Both aptamers and the random sequence were incubated with the cells for 
30 min and then imaged. Scale bars correspond to 25 μm in all images.
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aptamers and then probed with anti-MGB2 and anti-MGB1 respectively, the mean of fluorescence intensity 
decreased by almost 10-fold (Fig. 7B). Blocking with a random sequence restored the binding of anti-MGB2 to 
transfected MGB2 HEK293 cells (Fig. 7C dark yellow) same as the binding seen in Fig. 7A, suggesting that both 
MAMB1 and anti-MGB2 are competing for the same binding sites. This binding is specific as it was restored 
when a random sequence was used for blocking (Fig. 7C). A small shift in the mean of fluorescence intensity of 
anti-MGB1 binding to transfected MGB1 HEK 293 cells was seen when the same random sequence was used 
to blocked the binding sites of MGB1 on transfected MGB1 HEK293 cells (Fig. 7C, light blue). This could be 
non-specific binding of the random sequence to MGB1 sites on transfected MGB1 HEK293 cells. Other random 
sequences could be used in the future to restore the original binding seen in Fig. 7A.
pUC19-transfected HEK293 results showed no binding to MAMB1, MAMA2, anti MGB2, and anti-MGB1 
probes (Supplementary Fig. S7). Moreover, no binding was seen when pUC19-transfected HEK293 cells were 
blocked with either unlabeled MAMB1 and MAMB1 aptamers or with a random sequence. pUC19 did not 
contain either MGB2 or MGB1 genes and therefore MGB2 and MGB1 were not expressed on the surface of 
HEK293 cells. The mean of fluorescence intensity of pUC19 transfected HEK293 cells was close to the one for 
non-transfected HEK293 cells (Fig. 6A).
To investigate the selectivity of both aptamers and antibodies, the binding of MAMB1 and MAMA2 to trans-
fected MGB1 and transfected MGB2 HEK293, respectively, was tested (Fig. 8). The results showed that MAMB1 
did not bind to transfected MGB1 HEK293 cells (Fig. 8, black), and the same was observed for MAMA2 aptamer 
(Fig. 8, pink). This was expected as steps were taken in SELEX to eliminate sequences that could bind to both 
MGB2 and MGB1 proteins together. The MGB2 and anti-MGB1 to transfected MGB1 (Fig. 8, dark yellow) and 
transfected MGB2 HEK293 cells (Fig. 8, purple) respectively, showed a small shift in the mean of fluorescence 
intensity. This could be as a result of non-specific binding of both antibodies to their counter proteins. These 
results indicate that both MAMB1 and MAMA2 aptamers are more selective than their antibodies counterparts. 
In summary, our aptamer–antibody competition binding assay results confirmed that MGB2 and MGB1 proteins 
are the targets of MAMB1 and MAMA2 aptamers respectively.
Binding of MAMB1 and MAMA2 to breast cancer cells in plasma and whole blood lysate. The 
ability of MAMB1 and MAMA2 to bind selectively to breast cancer cells in plasma and whole blood lysate was 
investigated using peripheral blood mononuclear cells (PBMC), which represent normal peripheral blood cells 
and include mainly lymphocytes (T cells, B cells, natural killer cells) and monocytes. These cells were used as 
the control (i.e. non-cancerous cells). MCF7 and MDA-MB-415 were used as the target breast cancer cells for 
MAMB1 and MAMA2 aptamers, respectively.
Figure 6. Binding of MAMB1, MAMA2 aptamers and MGB2, MGB1 antibodies to nontransfected HEK293, 
MCF7, and MDA-MB-415 cells. (A) Mean of fluorescence intensity of non-transfected HEK293 cells (black), 
MCF7 (red), and MDA-MB-415 (blue) without probes (cells only). (B) Mean of fluorescence intensity of non-
transfected HEK293 cells binding to MAMB1 (black), MAMA2 (green), MCF7 binding to MAMB1 (red), and 
MDA-MB-415 binding to MAMA2 (blue). (C) Mean of fluorescence intensity of non-transfected HEK293 cells 
binding to anti-MGB1 antibody (black), anti MGB2 antibody (green), MCF7 binding to anti MGB2 antibody 
(red), and MDA-MB-415 binding to MGB1 antibody (blue). (D) Mean of fluorescence intensity of non-
transfected HEK293 cells (black), MCF7 (red), and MDA-MB- 415 (blue) binding to a random sequence. Cells 
were incubated with their corresponding probes and 10000 events was counted by flow cytometry. Then data 
was analyzed using flow cytometry C6 sampler software.
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The human plasma used in this study was prepared from pooled human blood (Sigma Aldrich, Canada) 
and contained active clotting factors. The ability of MAMB1 and MAMA2 to bind to their target breast cancer 
cells in plasma was first investigated. The study aimed to provide a proof-of-concept, demonstrating the selec-
tive binding of MAMB1 and MAMA2 aptamers to their specific cell lines, in a series of different environments, 
starting with least complex to the most complex. Starting with plasma, as the least complex environment, 
MAMB1 and MAMA2 6-FAM labeled aptamers discriminate breast cancer cells against normal blood cells 
(PBMC) (spiked into the plasma as described in the methods section), as shown by the difference in mean 
of fluorescence intensity (Fig. 9). MAMB1 and MAMA2 behaved the same and showed significant binding 
(P < 0.05) to their target breast cancer cells at different cell numbers (1 × 104 and 1 × 103 cells) and different 
aptamer concentrations (25, 50, 200 nM). MAMB1 had a higher affinity to its target breast cancer cell line 
(MCF7) than MAMA2.
MGB1 and MGB2 were previously reported as biomarkers for CTCs in the blood of breast cancer patients24–28. 
As such, blood was selected as the second most complex environment to investigate the binding of MAMB1 
and MAMA2 aptamers to their breast cancer cells targets, in comparison to PBMC cells (cells were added to the 
blood lysate as described in the method section). The whole blood lysate experimental results showed that both 
Figure 7. Competition binding assays of MAMB1, MAMA2 aptamers and anti MGB, anti MGB1 antibodies on 
transfected HEK293 cells with MGB2 and MGB1 plasmids. (A) Mean of fluorescence intensity of transfected 
HEK293 with MGB2 plasmid (Trans B) binding to anti MGB2 (orange) and MAMB1 (purple), and transfected 
HEK293 with MGB1 plasmid (Trans A) binding to anti MGB1 (green) and MAMA2 (brown). (B) Mean of 
fluorescence intensity of Trans B and Trans A HEK293 blocked with unlabeled MAMB1 and MAMA2 aptamers 
respectively, and probed with anti MGB2 (red) in the case of Trans B, and anti MGB1 (brown) in the case of 
Trans A. Mean of fluorescence intensity of Trans B and Trans A binding to MAMB1 (purple), and MAMA2 
(brown) same as in A. (C) Mean of fluorescence intensity of Trans B and Trans A HEK293 blocked with random 
sequence (RAN) and probed with anti MGB2 (dark yellow) in the case of Trans B and anti MGB1 (light blue) 
in the case of Trans A. Mean of fluorescence intensity of Trans B and Trans A binding to MAMB1 (purple) and 
MAMA2 (brown) same as in A. Cells were incubated with their corresponding probes and 10000 events was 
counted by flow cytometry. Then data was analyzed using flow cytometry C6 sampler software.
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Figure 8. Selectivity test performed on transfected HEK293 cells with MGB2 and MGB1 plasmids. The figure 
shows the mean of fluorescence intensity of MAMB1 (black), MAMA2 (pink), anti MGB2 (dark yellow), and 
anti MGB1 (purple) binding to Trans A and Trans B HEK293 cells respectively. Cells were incubated with their 
counter probes transfected HEK293, and 10000 events was counted by flow cytometry. Then data was analyzed 
using flow cytometry C6 sampler software.
Figure 9. Binding of MAMB1 and MAMA2 aptamers to their breast cancer cells in plasma by flow cytometry. 
(A-C) Mean of fluorescence intensity of MDA-MB-415 cancer cells and PBMC normal cells at 200nM (A), 
50nM (B), and 25nM (C) concentrations of MAMA2 aptamer. (D–F) Mean of fluorescence intensity of MCF7 
cancer cells and PBMC normal cells at 200nM (D), 50nM (E), and 25nM (F) concentrations of MAMB1 
aptamer. Two cell numbers from both cancer and normal cells were used: 104 and 103 cells. Values are shown 
as means ± S.E.M. of three trials. The statistical significance was determined by one way ANOVA followed by 
Fisher LSD multiple tests using SPSS software (SPSS, version 23). P Values less than 0.05 were considered to be 
significantly different.
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aptamers bind specifically to their target breast cancer cells (Fig. 10). The mean of fluorescence intensity of cancer 
cells bound to both aptamers was significantly increasing (p < 0.05) with increasing the aptamer concentration 
(50, 100 nM) and number of cells (103, 104) for both cell lines (Fig. 10).
Our whole blood lysate might include nuclease enzymes that could degrade aptamers and interfere with 
their binding to breast cancer cells. It has been reported that chemical modification of aptamers could improve 
their binding capability and make them more resistant to nucleases49,50. In the present study, both aptamers were 
chemically unmodified, with the only modification being the labelling with 6-FAM for both. MAMA2 showed 
less affinity towards its target, compared to MAMB1, in both plasma and whole blood lysate and it may require 
modification to improve its binding affinity. Nevertheless, fluorescence intensity values for both aptamers bind-
ing in whole blood lysate was comparable to that seen in plasma, indicative that, overall, MAMB1 and MAMA2 
aptamers showed great potential as detection tools for breast cancer cells in the plasma and whole blood lysate. To 
date, no study has been done to detect MGB1 and MGB2 in the blood or plasma of breast cancer patients, based 
on cell recognition, using flow cytometry.
Binding of MAMB1 and MAMA2 to spiked breast cancer cells in whole blood lysate. The selec-
tive binding of MAMB1 and MAMA2 aptamers were further tested in an environment in which MCF7 and 
MDA-MB-415 (positive cells) were spiked in different percentages (0, 0.01, 0.1, 1, 5, 10, 50, and 100) in whole 
Figure 10. Binding of MAMB1 and MAMA2 aptamers to their breast cancer cells in whole Blood lysate by 
flow cytometry. (A–C) Mean of fluorescence intensity of MDA-MB-415 cancer cells and PBMC normal cells 
at 200 nM (A), 100 nM (B) and 50 nM (C) concentrations of MAMA2 aptamer. (D–F) Mean of fluorescence 
intensity of MCF7 cancer cells and PBMC normal cells at 200nM (D), 100nM (E) and 50nM (F) concentrations 
of MAMB1 aptamer. Two cell numbers from both cancer and normal cells were used: 104 and 103 cells. Values 
are shown as means ± S.E.M. of three trials. The statistical significance was determined by one way ANOVA 
followed by Fisher LSD multiple tests using SPSS software (SPSS, version 23). P Values less than 0.05 were 
considered to be significantly different.
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blood lysate containing PBMC cells (that were added to the blood initially), and then incubated with 200 nM of 
MAMB1 and MAMA2 aptamers, respectively. The results obtained showed that the percentages of positive cells 
(output cells recognized by 6-FAM labeled aptamers) identified by the flow, increased with increasing number 
of spiked breast cancer cells (percentage of input cells) from 3.1% (for PBMC cells in blood lysate) (Fig. 11A) 
to 93.0% (for MCF7 cells in blood lysate) (Fig. 11H) for MAMB1 aptamers, and from 2.9% (for PBMC cells 
in blood lysate) (Fig. 12A) to 93.0% (for MDA-MB-415 in blood lysate) (Fig. 12H) for MAMA2 aptamer. The 
relationship between the percentage of spiked cancer cells (X-axis) and the percentage of positive cells identified 
(Y-axis) was linear (Figs 8I and 9I). MAMB1 and MAMA2 aptamers showed significant binding (P < 0.05) to 
spiked MCF7 and MDA-MB-415 cancer cells respectively in whole blood lysate containing PBMC cells at 5, 
10, 50, and 100%. It has been reported that CTCs were detected at 10% using flow cytometry51. In our study, 
Figure 11. Selective recognition of MCF7 cells in mixed cell samples with the 6-FAM labelled MAMB1 
aptamer in whole blood lysate. Cell mixture samples containing MCF7 and PBMC were prepared in different 
percentages of MCF7 ((A–G) 0%, 0.01%, 0.1%, 1%, 5%, 10%, 50%, and 100%). (I) plot of the percentage of 
cancer cells (MCF7) spiked (X-axis) and the percentage of positive cells identified (Y-axis). Values are shown 
as means ± S.E.M. of three trials. The statistical significance was determined by one way ANOVA followed by 
Fisher LSD multiple tests using SPSS software (SPSS, version 23). P Values less than 0.05 were considered to be 
significantly different.
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we significantly (P < 0.05) detected CTCs at 5%. The detection at 0.01, 0.1, and 1% was approaching significant 
(P = 0.07). Indicating that both aptamers could be used in a platform to detect CTCs from breast cancer.
Conclusion
In summary, a hybrid-SELEX approach was successfully used to select aptamers (MAMB1 and MAMA2) that 
target MGB2 and MGB1 biomarkers expressed on the surface of MCF7 and MDA-MB-415 cells, respectively. The 
target of these aptamers was confirmed by EMSA with their respective recombinant proteins, and by flow cytom-
etry after transfection of MGB2 and MGB1 plasmids into HEK293 cells. The selected aptamers showed high affin-
ity to their targets on the surface of the cells (Kd of low nanomolar range values), as well as to their free proteins. 
Figure 12. Selective recognition of MDA-MB-415 cells in mixed cell samples with the 6-FAM labelled MAMA2 
aptamer in whole blood lysate. Cell mixture samples containing MDA-MB-415 and PBMC were prepared in 
different percentages of MDA-MB-415 ((A–G) 0%, 0.01%, 0.1%, 1%, 5%, 10%, 50%, and 100%). (I) Plot of the 
percentage of cancer cells (MDA-MB-415) spiked (X-axis) and the percentage of positive cells identified by the 
MAMA2 aptamer (Y-axis). Values are shown as means ± S.E.M. of three trials. The statistical significance was 
determined by one way ANOVA followed by Fisher LSD multiple tests using SPSS software (SPSS, version 23). P 
Values less than 0.05 were considered to be significantly different.
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Both aptamers showed binding with high specificity and selectivity to breast cancer cells (as compared to normal 
breast cells, other cancer cell lines and non-cancer cells) using flow cytometry and fluorescence microscopy. Both 
aptamers were able to effectively discriminate breast cancer cells from normal blood cells. Moreover, the potential 
of both aptamers to bind to spiked breast cancer cells in whole blood lysate revealed the possibility of using both 
aptamers as CTC markers for the early detection of breast cancer.
Materials and Methods
Cell lines and cell culture. All cell lines were purchased from American Type Culture Collection (ATCC) 
unless otherwise indicated. MCF-7, (breast adenocarcinoma, derived from metastatic site: pleural effusion), 
MDA-MB-415 (breast adenocarcinoma, derived from metastatic site: pleural effusion), were used as the target 
cell lines. MCF-10A (derived from mammary gland; breast) and HCAEC (Human Coronary Artery Endothelial 
Cells; primary cells) cell lines were both used as counter selection lines. The following cells lines were used in 
specificity tests: HepG2 (hepatocellular carcinoma), HeLa (human cervical carcinoma), HEK293 (human embry-
onic kidney), WI-38 (human lung normal) and MDA-MB-231 (breast adenocarcinoma, derived from metastatic 
site: pleural effusion) which was obtained as a frozen stock from Dr. Christine Pratt (Cellular and Molecular 
Medicine, University of Ottawa, Canada). Human Primary Peripheral Blood Mononuclear Cells (PBMC) (nor-
mal) were used in the blood and plasma experiments.
MCF7, MDA-MB-415, MDA-MB-231, HepG2, HeLa, HEK293 cells were cultured in DMEM. Human recom-
binant insulin (0.01 mg/ml) was added as supplement to only MCF7 and MDA-MB-415. WI-38 cells were cul-
tured in EMEM medium. Fetal bovine serum (FBS; 10%) was added to the media of all the above cell lines. 
MCF10A cells were cultured in Mammalian Epithelial Cell Growth Medium kit (Lonza). HCAEC were cultured 
in MV2 basal medium kit (PromoCell). PBMC cells were cultured in Hank’s balanced salt solution. All cells were 
cultured in a 5% CO2, 95% humidified chamber at 37 °C.
DNA Synthesis. The ssDNA library was prepared with a 24 nucleotide randomized sequence (N), 
flanked by two 20-nucleotide primer binding sites. ssDNA library: 5′-CATGCTTACCTATAGTGAAC (N24) 
CTTTGAGAACTGACTCTAC-3′, the forward primer was labelled on the 5′ end with fluorescein to moni-
tor the library enrichment during SELEX (5′-(6-FAM)-CATGCTTACCTATAGTGAAC-3′). Twenty adenine 
nucleotides and a hexaethyleneglycol (HGE) linker were added to the reverse primer at the 5′ end (5′-(A20)-
HEG-GTATGAGTCAGTTCTCAAAG-3′) to be able to separate the forward from reverse strands by denatur-
ing PAGE (12% at 250 V, 3 hrs).6-FAM was added to the five prime ends to all the synthesized aptamers. The 
MerMade 6 automated DNA synthesizer (Bioautomation, USA) was used to synthesize all DNA sequences and 
the library.
Hybrid-SELEX approach. Purified GST tagged recombinant MGB2 protein (target protein), and purified 
GST protein (counter selection target) were conjugated to glutathione-agarose beads by incubating 16 µg of GST 
protein and 9 µg of MGB2 in 100 µL of the beads in binding buffer (150 mM Tris, 150 mM NaCl, 5 mM KCl, 
5 mM MgCl2, pH 7.4) at RT for 30 min. Beads were then centrifuged (21000 × g for 2 min) and supernatant 
was kept for protein measurement at 280 nm. SELEX was initiated with a counter selection round by incubating 
GST-conjugated beads (100 µL) with a ssDNA library (5 nmol) which was heated at 95 °C for 5 min and then 
gradually cooled to 4 °C for 10 min and another 10 min at room temperature. The mixture was then incubated at 
room temperature in binding buffer for 60 min. The supernatant was then subjected to further positive selection 
by incubating it with purified GST-tagged MGB2 protein-conjugated beads (beads after conjugation above) for 
30 min at room temperature. A partitioning step took place by washing the beads with washing buffer (same 
as the binding buffer). The protein-DNA complex was then eluted from the beads (5 times 100 µL each) using 
elution buffer (7 M urea, 5 mM EDTA) heated to 95 °C, followed by phenol-chloroform extraction and ethanol 
precipitation52. The eluted DNA was then amplified by PCR using the following conditions: 95 °C for 30 s, 58 °C 
for 30 s, and 72 °C for 30 s for 25 cycles, followed by extension step at 72 °C for 10 min. The SELEX was repeated 
for 21 rounds and the counter selection step was repeated every round, along the positive selection step. MGB1 
protein-conjugated beads were then used as a counter selection step instead of GST-conjugated beads in rounds 
16, 17 and 18 to remove aptamers targeting MGB1 protein, because of their high similarity, resulting in the 
separation of the initial ssDNA library into two halves. Another separate SELEX for MGB1 was performed in a 
manner similar to that for MGB2 SELEX, using four rounds of selection and GST-conjugated beads as the coun-
ter selection in every round (Fig. 1). The stringency of MGB2 and MGB1 selection was increased by decreasing 
the concentration of the amplified ssDNA library (from 5 nmol to 100 pmol in the final pools) and the time of 
incubation for the positive targets (from 30 min to 15 min), and increasing the washing times (from 2 to 5 times) 
and volume (from 100 to 500 µL).
In order to obtain aptamers that bound to MGB2 and MGB1 on the surface of the cells, the final enriched 
DNA libraries resulting from protein SELEX were used as the initial pools for cell-SELEX. In cell-SELEX, two 
counter selection steps took place in which 2 × 106 cells of MCF-10A and HCAEC were incubated with 100 
pmol of the enriched libraries (after heating and cooling to room temperature) in binding buffer (4.5 g/L glucose, 
5 mM MgCl2, 2 mg/mL BSA, 0.2 mg/mL yeast tRNA, 200 µL of 10% FBS in PBS, pH 7.4) for 1 hour at 4 °C. The 
supernatants of MGB2 and MGB1 libraries were then incubated with 1 × 106 cells of MCF7 and MDA-MB-415, 
respectively in binding buffer for 30 min at 4 °C. Cells were then washed with washing buffer (4.5 g/L glucose, 
5 mM MgCl2 in PBS, pH 7.4) to remove any unbound sequences. Bound DNA was then eluted in washing buffer 
by heating at 95 °C for 5 min. The supernatant was then collected and amplified by PCR using the same conditions 
as in the protein-SELEX, but the number of cycles was reduced to 20. The cell-SELEX was repeated for 7 rounds 
for both MCF7 (MGB2) and MDA-MB-415 (MGB1) cell lines. The enrichment of both libraries was gradually 
increased during SELEX by reducing the amount of both pools (from 100 to 50 pmol), the incubation time for 
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the target cells (from 30 to 15 min), and the target cell number (from 1 × 106 to 1 × 105 cells) and by increasing 
the number of washes (from three to six). To eliminate the off-target binding aptamers that might result from 
cell-SELEX, an additional 2 rounds of purified protein-SELEX were performed to further focus the ssDNA pools 
specifically toward MGB2 and MGB1 (Fig. 1).
Monitoring the enrichment of hybrid SELEX. MCF7, MDA-MB-415, HCAEC, and MCF10A cells 
(2 × 105 cells) were incubated with 200 nM of ssDNA libraries and 0.3 mg/mL of ssDNA from salmon sperm, 
0.5 mg/mL bovine serum albumin (BSA) for 30 min at 4 °C. Then cells were washed and re-suspended in 250 µL 
of binding buffer. Fluorescence intensity was analyzed from a minimum of 10000 cells using a BD Accuri C6 
benchtop flow cytometer and C6 sampler software (BD, USA). Round 0 ssDNA library was used as the negative 
control and treated same way as the ssDNA libraries from cell SELEX.
High throughput sequencing. High throughput sequencing (HTS) was performed using Illumina 
sequencing. Briefly, the enriched ssDNA pools from different rounds of selection (protein and cell-SELEX) for 
MGB2 (R0, R16, R16 counter selection, R30, R30 counter selection) and MGB1 (R17 counter selection of MGB1, 
R4, R5, R7, R10, R11, R12, R13 counter selection) SELEX were PCR amplified using Illumina special adaptors 
(TruSeq primers) to a minimum number of cycles (17 cycles). PCR products were purified using PAGE and 
the DNA quantified using a Nanodrop spectrophotometer (Thermo Fisher, Canada). All MGB1 amplified pools 
were combined and all MGB2 amplified pools were combined separately to provide a total of 75 ng of DNA in 
each pool. Amplified pools were then sent to Genome Quebec Facility (Quebec, Canada) to be sequenced using 
Illumina HiSeq sequencing platform. AptaCluster was used as the software to analyze the sequencing data and 
RNAstructure software (Mathews Lab RNAstructure) was used to predict the secondary structure of the candi-
date sequences.
Assessment of the binding affinity and selectivity (cell type). All selected aptamers were evaluated 
for their binding affinity in a screening test by flow cytometry in which the fluorescence intensity was determined 
for all selected aptamers against positive and counter selection cell lines. Second, aptamers that showed high bind-
ing affinity to positive cell lines and minimum non-specific binding to counter cell lines were chose to determine 
their apparent dissociation constants (Kd) using different concentrations of the aptamers (0, 5, 10, 40, 60, 100, 140, 
160, 180, 200 nM) that were incubated with fixed MCF7 and MDA-MB-415 cells (2 × 105) in 200 µL total volume 
of binding buffer. Round 0 was used as the control and incubated with the same concentrations of aptamers.
To assess the selectivity of the aptamers, the remaining aptamers were incubated with all other cell lines 
(2 × 105 fixed cells in 200 µL in binding buffer) mentioned above and were subjected to determination of the 
binding affinity by flow cytometry.
Assessment of binding (recombinant protein). Electrophoretic mobility shift assay (EMSA) was used 
to investigate the binding of selected aptamers to their target recombinant proteins (MGB2 and MGB1). Briefly, 
different concentrations of target proteins (0 to 220 nM) were incubated with a fixed aptamer concentration 
(600 nM) in 50 mM Tris-HCl, 10 mM reduced glutathione, pH 8.0 for 1 hr at 37 °C. Protein-aptamer complex 
samples were then loaded to 8% non-denaturing polyacrylamide gel and allowed to run for 3 hrs at 160 V at room 
temperature. Gels were then visualized using an Alpha Innotech gel imager documentation system (USA). ssDNA 
aptamer against dopamine (60 bases45) and BSA protein were used as controls by incubating them with increasing 
concentrations of the same target proteins and treated the same way as the experimental aptamers.
Binding of MAMB1 and MAMA2 to their target breast cancer cells by fluorescence micros-
copy. The binding of MAMB1 and MAMA2 to their target breast cancer cells was further by fluorescence 
microscopy. Briefly, cells (5 × 105) were plated on coverslips in 35 mm tissue culture dishes and let to grow for 
24 hours, cells then were washed with PBS and fixed in 4% formaldehyde solution for 15 min at RT. Aptamers 
were added for 30 min at RT at concentration of 300 nM in binding buffer. Cells then were washed three times 
with cold PBS, then 4′,6-diamidino-2-phenylindole (DAPI) (10 mg/mL diluted 1:20,000) was added for 5 min. 
Cells then were washed three times each 5 min using deionized water. Then coverslips were mounted on micro-
scope slides using VECTASHIELD mounting medium (Vector laboratories, USA) and imaged using ZOE™ flu-
orescent cell Imager (Bio-Rad, Canada) using the green and blue channels.
MCF7 and MDA-MB-415 were used as the target breast cancer cells lines for MAMB1 and MAMA2 respec-
tively, HCAEC, MCF10A, HEK293, WI38, MDA-MB-231 and HepG2 cell lines were used to test the selectivity 
of both aptamers. Random sequence (dopamine aptamer) was used as control, which was incubated same way as 
the aptamers with each cell line and imaged using fluorescence microscopy.
Binding of MAMB1 and MAMA2 to their target breast cancer cell lines in plasma and whole 
blood lysate. Lyophilized human plasma (Sigma Aldrich) was dissolved in 5 mL of deionized water on a 
shaker for 2 hrs at room temperature. According to the source of lyophilized human blood sample, the blood sam-
ple was blood obtained from a normal human donor that was freeze dried. All the components of normal blood 
were there including cells and plasma proteins (such as albumins, globulins, fibrinogen) but the cells, in this case, 
are lysed (dead). The sample was dissolved in 3 mL of deionized water on a shaker for 3 hrs at room temperature. 
A smear of the reconstituted blood was made to check for the existence of cells. Blood samples were then lysed 
using RBC lysis buffer (154 mM NH4Cl, 5.7 mM K2HPO4, 0.1 mM EDTA).
MCF7, MDA-MB-415, and PBMC cells were harvested and fixed in 4% formaldehyde solution in PBS for 
15 min at room temperature. Cells then were centrifuged at 1,000 × g for 5 min, and re-suspended in human 
whole blood lysate and human plasma prepared previously (1 mL each). The total number of cells from each cell 
line was 1 × 107. Then cell-whole blood lysate and cell-plasma suspensions from all three cell lines was used as 
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stocks to prepare two numbers of cells which are 1 × 103 and 1 × 104 cells from each cell line. For whole blood 
lysate experiments, MAMB1 and MAMA2 aptamers (heated at 95 °C and gradually cooled down 10 min at 4 °C 
and 10 min at room temperature prior to use) were incubated with the different numbers of cells from each cor-
responding cell line (MAMB1 with MCF7 and MAMA2 with MDA-MB-415) at concentrations of 200, 100, and 
50 nM final concentrations and 250 µL final volume at 4 °C for 15 min. The plasma experiments had the same pro-
cedure applied as mentioned above, but the final concentrations of the aptamers were 200, 50, and 25 nM. PBMC 
cells were used as the control for both plasma and whole blood lysate experiments and they were treated same way 
as the target cells. After incubation, all samples were subjected to flow cytometry analysis.
Binding of MAMB1 and MAMA2 to their spiked breast cancer cells in whole blood lysate. Breast 
cancer cells were harvested and fixed same way as in the plasma and whole blood lysate experiments. MCF7 and 
MDA-MB-415 cells were then spiked in different percentages in PBMC cells-whole blood lysate suspension to a 
total number of 1 × 104 cells. The percentages of spiked cancer cells, for each type of cells, were 0.01, 0.1, 1, 5, 10, 
50, and 100%. MAMB1 and MAMA2 aptamers (200 nM each) were incubated with their corresponding spiked 
breast cancer cells in whole blood lysate in a total volume of 250 µL for 15 min at room temperature. Cells were 
then used for flow cytometry analysis.
Aptamers cells binding studies to identify the targets on the surface of breast cancer 
cells. HEK293 cells were chosen to perform the aptamers cells binding studies. The expression levels of both 
proteins MGB2 and MGB1 was evaluated using ELISA kits for both proteins. MGB2 and MGB1 plasmids were 
then used to transfect HEK293 cells. Briefly, HEK293 cells (5 × 105) were plated in 60 mm tissue culture dishes 
and left to grow for 24 hours in the incubator (37 °C and 5% CO2). Then, next day the old DMEM medium 
was replaced with new one (5 mL) and HEK 293 cells were left in the incubator for 30 min. The DNA (plas-
mids) were prepared for transfection; 10 µg of each purified MGB1 and MGB2 plasmids were added to 250 µL of 
Opti-MEM media, then 50 µL (final concentration of 5 µg/mL) of polyethylenimine (PEI) was added to 250 µL 
of Opti-MEM media in a separate tube. Then PEI was added to the DNA (plasmids) and incubated for 15 min at 
RT. The PEI-DNA was mixed by vortex every 3 min for 5 sec. After that, the PEI-DNA complex was added to the 
cells gradually drop by drop, and then HEK293 cells were left to grow for 48 hours. pUC19 empty vector was used 
as control. green fluorescence protein (GFP) was used to validate the transfection efficiency. Both pUC19 and 
GFP plasmids were transfected using the same amount of DNA as MGB2 and MGB1 plasmids under the same 
conditions and time. After 48 hours, HEK293 cells were harvested and fixed with 4% formaldehyde for 15 min at 
RT. Then washed and re-suspend in PBS to be used in flow cytometry analysis.
For aptamers antibodies competition studies, anti MGB2 and anti MGB1 monoclonal antibodies, goat 
anti-mouse FITC labelled secondary antibody, 6-FAM-labelled and unlabeled MAMB1 and MAMA2 aptam-
ers, non-transfected and transfected HEK293 cells as well as MCF7 and MDA-MB-415 were used in compe-
tition study. Briefly, 5 × 105 fixed cells of each cell line mentioned above was added to 500 µL of 5 mM MgCl2 
in PBS, then competition studies were performed as the following. 1): non-transfected HEK293, MCF7 and 
MDA-MB-415 cells were incubated with 300 nM of 6-FAM labelled aptamers (MAMB1 with MCF7, MAMA2 
with MDA-MB-415, and each of them with HEK293) or a control random sequence for 30 min at 4 °C, 
then centrifuged at 1,000 xg for 5 min, cells then were re-suspended with 500 µL of 5 mM MgCl2 in PBS. 2): 
non-transfected HEK293, MCF7 and MDA-MB-415 cells were incubated with anti-MGB2 and MGB1 primary 
monoclonal antibodies (1:400 of 100 µg, anti-MGB2 with MCF7, anti MGB1 with MDA-MB-415, and each of 
them with HEK293) for 30 min at RT. Cells then were centrifuged 1,000 xg for 5 min and washed three times with 
PBS. Goat anti mouse FITC labelled secondary antibody (1:500 of 100 µg) was added for 20 min at RT. Finally, 
cells were centrifuged and washed as above, then re-suspended with 500 µL of PBS. 3): transfected HEK293 were 
incubated with either 300 nM 6-FAM labelled aptamers, or unlabeled aptamers, or random sequence for 30 min at 
4 °C, then they were incubated with anti-MGB2 or MGB1 primary monoclonal antibodies, then goat anti-mouse 
FITC labelled secondary antibody, applying same conditions as in 2). All cells were studied using flow cytometry 
by counting 10,000 events and data were analyzed using the flow cytometry C6 sampler software. The fluores-
cence intensity of goat anti mouse secondary antibody alone was subtracted from the samples where primary and 
secondary antibodies were used together to obtain the fluorescence intensity for the primary antinodes alone.
Statistical analysis. All data represent the average ± S.E.M. The binding affinity (Kd) graphed were plotted 
using GraphPad Prism software (USA). The statistical significance was determined using a one-way ANOVA 
followed by the Fisher LSD test using SPSS software (SPSS, version 23). A p value of less than 0.05 was considered 
to be significant. All plasma and whole blood lysate experiments results were plotted using MS-Excel 2013. BD 
Accuri™ C6 Software (Version 227) was used to analyze all flow cytometry data.
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